MedPath

Surfactant Administration During Spontaneous Breathing

Phase 4
Conditions
Pneumothorax
Pulmonary Interstitial Emphysema
Bronchopulmonary Dysplasia
Interventions
Procedure: Take care
Procedure: InSurE
Registration Number
NCT01329432
Lead Sponsor
Zekai Tahir Burak Women's Health Research and Education Hospital
Brief Summary

Spontaneous breathing supported by nasal continuous positive airway pressure (nCPAP) is thought to have some advantages compared with mechanical ventilation in premature infants. In addition, early surfactant administration has been shown to be superior to delayed use. The aim of this pilot study was to describe the feasibility of TAKE CARE (early administration of surfactant in spontaneous breathing) procedure and compare its short-term and long-term results with InSurE procedure.

Detailed Description

In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing. In the control group infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration. The procedures were compared for short-term efficacy and possible complications.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • All infants who presented with clinical anl laboratory signs of RDS
Exclusion Criteria
  • infants who required intubation or PPV right after birth

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
take careTake careIn TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing
InSurEInSurEinfants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration
Primary Outcome Measures
NameTimeMethod
nasal cPAP failure and need for mechanical ventilation within 72 hoursfirst 72 hours
Secondary Outcome Measures
NameTimeMethod
incidence of bronchopulmonary dysplasia8-10 weeks

Trial Locations

Locations (1)

Zekai tahir Burak Materntiy Teaching Hospital, Neonatal Intensive Care Unit

🇹🇷

Ankara, Turkey

© Copyright 2025. All Rights Reserved by MedPath